

27 October 2023

Secondary Trading Notice Pursuant to Section 708A(5)(e) of the Corporations Act

Melodiol Global Health Limited (ASX:ME1, FRA:1X8) ('Melodiol' or 'the Company') gives this notice pursuant to section 708A(5)(e) of the Corporations Act 2001 (Cth) ('Corporations Act').

The Company advises that it has issued ordinary fully paid shares in the capital of the Company, per the Appendix 2As lodged with the ASX on 27 October 2023 ("Shares"). The Shares were issued without disclosure under Part 6D.2 of the Act.

The Company, as at the date of this notice, has complied with:

- (a) the provisions of Chapter 2M of the Act as they apply to the Company; and
- (b) section 674 and 674A of the Corporations Act.

As at the date of this notice, other than as set out below, there is no information to be disclosed which is excluded information (as defined in section 708A(7) of the Corporations Act) that is reasonable for investors and their professional advisers to expect to find in a disclosure document.

The Company notes that the terms for the extension of the maturity date with the Secured Note Holders (refer to ASX Announcement: 26 October 2023) required that the Secured Note Holders be issued the 100 million Shares by 23 October 2023. Due to an administrative issue, the Shares were not allocated to the Secured Note Holders' required holder identification number (HIN) at re-commencement of trade on 26 October 2023. The matter has been rectified, and the Company has since agreed to issue the Secured Note Holders 48 million Shares (at a deemed issue price of \$0.004) as compensation for the delay. 20 million Shares will be issued imminently pursuant to the Company's Listing Rule 7.1 capacity, with the remaining 28 million Shares subject to prior shareholder approval. The Secured Note Holders will be entitled to receive one free attaching option (on the same terms as the ME1OE options announced on 23 October 2023) for every one Share issued. The issuance of these options will be subject to prior shareholder approval.

-Ends-

Authority and Contact Details

This announcement has been authorised for release by Managing Director, William Lay.

For further information, please contact:

Investor Enquiries

Melodiol Global Health Limited

E: info@cresopharma.com

P: +61 (0) 497 571 532

About Melodiol

Melodiol Global Health Limited (ASX:ME1) brings the best of cannabis and other plant-based products to better the lives of people and animals. Melodiol strives for the highest quality in its products. It develops cannabis, hemp-derived and other plant based therapeutic, nutraceutical, and lifestyle products with wide consumer reach.

To learn more please visit: <https://melodiolglobalhealth.com/>

Melodiol offices:

Australia: Suite 5 CPC, 145 Stirling Hwy, Nedlands, WA, 6009

Canada: 59 Payzant Drive, Windsor, Nova Scotia, B0N 2T0 and 50 Ivey Ln, Windsor, Nova Scotia, B0N 2T0

Forward Looking statements

This announcement contains forward-looking statements with respect to Melodiol and its respective operations, strategy, investments, financial performance and condition.

These statements generally can be identified by use of forward-looking words such as "may", "will", "expect", "estimate", "anticipate", "intends", "believe" or "continue" or the negative thereof or similar variations. The actual results and performance of Melodiol could differ materially from those expressed or implied by such statements. Such statements are qualified in their entirety by the inherent risks and uncertainties surrounding future expectations. Some important factors that could cause actual results to differ materially from expectations include, among other things, general economic and market factors, competition and government regulation.

The cautionary statements qualify all forward-looking statements attributable to Melodiol and persons acting on its behalf. Unless otherwise stated, all forward-looking statements speak only as of the date of this announcement and Melodiol has no obligation to up-date such statements, except to the extent required by applicable laws.